Plixorafenib Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: FORE8394, PLX8394

Pipeline

Early 1: 1Phase 2: 1

Top Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
Fore Biotherapeutics1

Indications

Cancer2
BRAF V600E Mutation1
LGG1
HGG1
Cancer Harboring BRAF Alterations1

Beverly Hills, California1 trial

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Precision NextGen Oncology & Research Center

Phase 2

Baltimore, Maryland1 trial

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Johns Hopkins

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.